sy1amino)-pyrimido[5.4-dlpyrimidine provide ID50 values against
t h e human lyaphoblast l i n e MI-L2 o f 0.18 u. 1 and 0.05 lltl.
respectively. Cultured MI-L2 and i n v i v o m u s e L1210 t u m r l i n e s selected f o r resistance t o these analogs are characterized by a deficiency i n adenosine kinase a c t i v i t y . These compounds completely i n h i b i t de novo purine and pyrimidine biosynthesis as wasured by [l4C]-bicarbonate incorporation and reduce by > 852 t h e r a t e o f i n c o r p o r a t i o n i n t o nucleotides o f e i t h e r [14C]-hypoxanthine. -adenine, o r -orotate and by > 601 [14C]-nicotinamide i n t o NAO; a requirement f o r PRPP i s coanan t o each of these incorporation pathways. I n c o n t r a s t t h e r a t e s o f incorporation o f [14C]-adenosine. -5-aminoimidazole-4-carboxa-
mide r i b o s i d e and -uridine, which do n o t r e q u i r e PRPP f o r incorporation, are r e l a t i v e l y unaffected. Treatment o f c e l l s w i t h t h e 4-amino analog causes a 502 reduction i n t h e PRPP pool and, i n studies o f inosine-driven, adenine incorporation by HPRT d e f i c i e n t c e l l s . > 951 reduction i n PRPP a v a i l a b i l i t y .
Studies w i t h t h e human erythrocyte PRPP synthetase i n d i c a t e t h a t a t physiological phosphate concentrations, 1 -5 d l , t h e monophospha,te form o f these adenosine analogs maintains t h e enzyme i n an i n a c t i v e f o m . A t h i g h phosphate concentrations, > 32 nt4, t h e monophosphates o f t h e analogs have no e f f e c t on t h e a c t i v i t y o f PRPP synthetase. One i n v i t r o model o f t h e chondro-osseous dysplasia (COD) seen i n adenosine deaminase deficiency i s characterized by d e p l e t i o n o f chondrocyte ATP. I f normal bone m i n e r a l i z a t i o n i s an energy dependant process, low growth p l a t e ATP concentration could be a p a r t i a l basis f o r COD. Since c a r t i l a g e m a t r i x vesicles (MV) are involved i n m i n e r a l i z a t i o n o f growth c a r t i l a g e and MV possess an ensemble o f membrane bound purine nucleotide-processing enzymes i n c l u d i n g ATP pyrophosphohydrolase, 5'nucleotidase and a l k a l i n e phosphatase, we investigated whether ATP was required f o r MV mineralization.
MV were prepared by u l t r a c e n t r i f u g a t i o n o f collagenase-digested a d u l t porcine hyaline a r t i c u l a r c a r t i l a g e . M i n e r a l i z a t i o n experiments were conducted i n inorganic phosphate (Pi)-free media containing 2.2nlM "Ca a t ph 7.6 and 37' C. Additions o f ATP, AMP, Pi, aO-methylene ATP were made i n various experiments. M i n e r a l i z a t i o n was expressed as 'I5Ca uptake i n MV separated by 0.45 micron membrane f i l t r a t i o n . M i n e r a l i z a t i o n occured by 6 hours i n t h e presence o f 0.5-1.5 mM ATP o r Oymethylene ATP but not w i t h s t o i c h i o m e t r i c added P i alone. M i n e r a l i z a t i o n was i n h i b i t e d by 5 m M ATP. AMP alone only poorly supported mineralization, and no m i n e r a l i z a t i o n was observed w i t h aB-methylene ATP.
ATP requirement f o r M V m i n e r a l i z a t i o n i n d i c a t e s t h e p o t e n t i a l importance o f t h i s simple model i n studing the mechanisms o f d e f e c t i v e bone-formation i n COD. We measured synovial f l u i d (SF) 5NT and nucleotide pyrophosphohydrolase (NPPH), another c a r t i l a g e ectoenzyme associated w i t h CPPD deposition, i n 173 p a t i e n t s w i t h well-characterized arthropathies. A c y t o s o l i c enzyme, adenosine deaminase (ADA), and an ectoenzyme not associated w i t h CPPD deposition, a l k a l i n e phosphatase (AP), were measured as controls.
Enzyme A c t i v i t y , mean+SD(n), nmol/hr/mg p r o t e i n NPPH 5NT AP ADA aout 1.210.8(10) 1.7+1.3( 7) 10.2+2.6(6) 11.69.9( 6) ;suedogout 1.8+0.9( 7 j 2.5+i.oi 5 j 18.8+2.4i3j 10.4+5.2( 3 j R A 1.6+0.9(33) 3.8+1.9 (21) Thus, the drugs interact with IMP dehydrogenase with higher affinities than the natural metabolites, RMP or BMP with IMP-XMP and TAD with NADR site. Preincubation of the purified enzyme with RMP enhanced its inhibitory effect in a time-dependent manner.
and NPPH a c t i v i t i e s are highest and ADA a c t i v i t i e s are lowest i n j o i n t s w i t h n o n i n f l a m a t o r y SF which contain calcium c r y s t a l s (Wilcoxon rank-sum, p<0.05). SF a c t i v i t i e s correspond w i t h those reported i n c a r t i l a g e and suggest a s p e c i f i c associat i o n o f elevated SF 5NT and NPPll a c t i v i t i e s w i t h a r t i c u l a r calctum
The enzyme was protected from inactivation by IMP or XMP but not by NAD or NADil. Ribavirin and tiazofurin together provided synergistic killing of hepatoma cells in clonogenic assays and the metabolic flux of de novo guanylate synthesis was also synergistically inhibited. The rcsults provide a biochemical basis for combination chemotherapy wiLh tiazofurin and ribavirin against the 2 different ligand sites of IMP dehydrogenase. Product-inhibition studies showed that XMP was cam etitive with IMP (Ki = 136 uM) and noncompetitive with N A D ' . NADH exerted uncompetitive inhibition with respect to IMP (Ki = 210 uM) and mixed type with NAD+ (Ki(s1ope) = 290 uM). This inhibirory pattern suggests an ordered Bi-Bi mechanism for the enzyme reaction in which IMP binds to the enzyme first, followed by N A D ' .
NADH dissociates from the ternary complex after rearrangement, and finally XMP is released. XMP interacts with the free enzyme and competes for the ligand site with IMP, while NADll binds to the enzyme XMP complex. (Supported by Outstanding Investigator Grant CA-42510 to G.W.)
